Google and Roche Put a Co-Scientist Workflow at the Center of Drug Design

Google and Roche are building a unified AI discovery loop that brings target work, molecule design, and experimental feedback into one workflow.

Updated

What is this trend?

Google and Roche are centering drug discovery on an AI co-scientist workflow that links target finding, molecule design, lab testing, and model updates in one loop.

  • Discovery is shifting from separate tools to one continuous AI-guided workflow.
  • Cheminformatics skills now cover search, curation, potency modeling, and synthesis planning.
  • Closed-loop design compresses iteration time from hypothesis to testable candidate.
  • Human scientists stay central, but their role shifts toward steering, filtering, and validating AI output.

What’s the latest?

Google and Roche advanced a unified discovery platform built around an AI-enabled “co-scientist” workflow that links target and biology discovery, candidate generation, experimental validation, and model refinement.

How it developed

  1. Simulation, AI operating layers, and lab automation redefine R&D work
  2. Closed-Loop R&D, Governed Labs, and Tighter Trade-Secret Controls Reshape Innovation

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by seniority.

Related trends

Stay ahead in Research & Development (R&D)

Get the weekly Research & Development (R&D) brief in your inbox — the developments, what they mean by seniority, and what to do next.